Gsk Plc · LSE:GSK
Gsk — Corporate Update (April 2020)
11 slides from Gsk's corporate update, April 2020
Slide 1: GSK COVID-19 Response
GSK COVID-19 Response April 2020
Slide 2: GSK's Approach to responding to COVID-19
GSK’s Approach to responding to COVID-19 To help people do more, feel better, live longer Business People Solutions Continuity 2
Slide 3: GSK pursuing solutions based on four principles
GSK pursuing solutions based on four principles Solutions Using our science, technology, portfolio and resources to support development of products for prevention and treatment of COVID-19 and the overall global response Working in Global Commitment Pandemic Partnership approach to Access preparedne
Slide 4: GSK adjuvant-based vaccine collaborations
GSK adjuvant-based vaccine collaborations Collaboration approach: • To explore potential development of adjuvanted COVID-19 vaccines • To support development of best vaccines in fastest way possible • GSK adjuvant technology proven in pandemic influenza H1N1: • less antigen needed • more vaccine dos
Slide 5: Key role of adjuvanted vaccine in pandemic response
Key role of adjuvanted vaccine in pandemic response 5
Slide 6: GSK and Sanofi in unprecedented collaboration to develop adjuvanted COVID-19 vaccine
GSK and Sanofi in unprecedented collaboration to develop adjuvanted COVID-19 vaccine Adjuvanted COVID-19 vaccine: + • Phase I clinical trials to start in H2 2020 • If successful and subject to • Two of the world’s biggest vaccine companies regulatory considerations, • Proven technologies companies a
Slide 7: Committed to availability, access and investing in global long-term pandemic preparedness
Committed to availability, access and investing in global long-term pandemic preparedness We do not expect to profit from the portfolio of Approach COVID-19 vaccines collaborations during the pandemic: • We will responsibly price our adjuvant Responsible Donations Investing in • We will make our adj
Slide 8: Collaboration with Vir Biotechnology to identify new solutions for coronaviruses
Collaboration with Vir Biotechnology to identify new solutions for coronaviruses* • + First priority: accelerate VIR-7831 and VIR-7832, two promising COVID- 19 antibody candidates, into Phase II clinical trials in next 3 - 5 months • Vir Biotechnology’s monoclonal antibody platform has proven succes
Slide 9: Therapeutics approach
Therapeutics approach Anti-viral Prevention or treatment of medicines secondary complications Selected GSK & ViiV assets Short-list of clinical-stage assets progressed to in-vitro testing against being reviewed for potential utility in the COVID-19 virus COVID-19 Underpinned by GSK participation in
Slide 10: Investing in global long-term pandemic preparedness
Investing in global long-term pandemic preparedness Rapid response and scale up plans Regulatory support Internal investments Research and Development OR External Manufacturing capacity partners Testing and Diagnostics Pandemic leadership organisations 10
Slide 11: GSK global and local community support
GSK global and local community support Donations Diagnostic testing Equipment and in kind $10m donation A new COVID-19 diagnosis lab Over 300,000 units of PPE to WHO COVID-19 In collaboration with AZ and donated globally Solidarity Response Fund Cambridge University to support UK testing Over £1.6m